Regeneron News and Research

RSS
Eylea can ease vision problems for wet AMD patients

Eylea can ease vision problems for wet AMD patients

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Regeneron Pharmaceuticals expands ophthalmology portfolio

Regeneron Pharmaceuticals expands ophthalmology portfolio

NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform

NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Regeneron fourth quarter total revenues increase to $415 million

Regeneron fourth quarter total revenues increase to $415 million

Bayer submits MAA in Europe for EYLEA to treat macular edema after CRVO

Bayer submits MAA in Europe for EYLEA to treat macular edema after CRVO

EC approves Regeneron’s EYLEA for treatment of wet AMD

EC approves Regeneron’s EYLEA for treatment of wet AMD

Ranibizumab injections keep those with AMD driving longer

Ranibizumab injections keep those with AMD driving longer

Regeneron reports total revenues of $304 million for second quarter 2012

Regeneron reports total revenues of $304 million for second quarter 2012

Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program

Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program

Positive results from Sanofi and Regeneron’s SAR236553/REGN727 Phase 2 trial on heFH

Positive results from Sanofi and Regeneron’s SAR236553/REGN727 Phase 2 trial on heFH

Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan

Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan

Regeneron, Sanofi announce clinical and regulatory update for ZALTRAP

Regeneron, Sanofi announce clinical and regulatory update for ZALTRAP

Experimental drugs from Sanofi and Regenron cut cholesterol in a new way

Experimental drugs from Sanofi and Regenron cut cholesterol in a new way

New cholesterol lowering drugs on the horizon

New cholesterol lowering drugs on the horizon

FDA panel favors continued research on novel pain medicine

FDA panel favors continued research on novel pain medicine

Australian TGA approves Bayer's EYLEA for treatment of wet AMD

Australian TGA approves Bayer's EYLEA for treatment of wet AMD

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron, Genentech enter non-exclusive license and partial settlement agreement for EYLEA

Regeneron, Genentech enter non-exclusive license and partial settlement agreement for EYLEA